
|Articles|October 5, 2010 (Updated: November 10, 2020)
Look for upcoming Practice & Policy in November edition of ONCOLOGY
Author(s)Michael Mccaughan
Second-Guessing FDA: CMS’ Expanding Regulatory Role
Advertisement
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA’s jurisdiction-and the health care reform implementation is bringing more of those cases to the fore...
Check out the complete article by an award-winning journalist in the upcoming edition of ONCOLOGY...
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
GLP-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways
2
Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC
3
Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer
4
What Were the Top 2026 ACSO Genitourinary Symposium Abstracts?
5























































